La cadena de opciones muestra datos clave de las opciones de acciones de Aptevo Therapeutics a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Aptevo Therapeutics..

Aptevo Therapeutics (NASDAQ:APVO) Bolsa, Cadena de Opciones

Aptevo Therapeutics

Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.

In,This,Photo,Illustration,,The,Bullish,Company,Logo,Is,Seen

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

ANGX

APVO

BIAF

BITF

BLSH

CBRL

CURX

DVLT

EDUC

ETNB

NBTX

RCAT

RMCF

SQFT

VMAR

WHLR

Bullish sorprende con beneficios y sus acciones suben en el premarket. También destacan movimientos en 89bio, Aptevo y Wheeler Real Estate.

Las acciones de Bullish (BLSH) suben más de un 12%; Aquí están 20 acciones que se mueven en premercado

Aptevo Therapeutics Inc

Press Releases

Mipletamig Demonstrates Compelling Clinical Activity in Frontline AML

Aptevo Therapeutics Announces $8 Million Offering Priced At-the-Market Under Nasdaq Rules

Aptevo Expands Differentiated CD3 Portfolio with APVO455, Advancing a Suite of Targeted T-cell Engagers

Aptevo Therapeutics Announces Closing of $8 Million Offering Priced At-the-Market Under Nasdaq Rules

Aptevo Therapeutics Reports 2Q25 Financial Results And Provides A Business Update

Aptevo Highlights APVO442, a CD3-Directed Preclinical Candidate for Prostate Cancer

Aptevo Unveils Two Next-Generation, Industry Leading Trispecifics, Expanding CD3 Oncology Pipeline to Five Molecules

Mipletamig Delivers 100% Remission Rate in Cohort 3 of RAINIER Trial for AML

TOMI Environmental Solutions (NASDAQ: TOMZ): The Next Era of Disinfection Technology – More Stocks Inside

Aptevo Presenting Scientific and Clinical Updates at SITC and ASH, also Participating in Leading Financial and Industry Conferences in the Fourth Quarter

AIHS

CHEK

NSRGY

PRSO

TOMZ

TURB

Allarity Therapeutics, Inc. - Common stock

Allarity Therapeutics

Apimeds Pharmaceuticals US, Inc. Common Stock

Apimeds Pharmaceuticals

BriaCell Therapeutics Corp. - Common Shares

BriaCell Therapeutics

Curis

Edesa Biotech

Fortress Biotech, Inc. - 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock

Fortress Biotech

FibroBiologics

Genprex

Geovax Labs

iBio

Kairos Pharma

Longeveron

Lixte Biotechnology Holdings, Inc. - Common Stock

Lixte Biotechnology

Lisata Therapeutics

Moleculin Biotech

Minerva Neurosciences, Inc - Common Stock

Minerva Neurosciences

NextCure

ProMIS Neurosciences Inc. - Common Shares

ProMIS Neurosciences

Propanc Biopharma

Rallybio

SAB Biotherapeutics

Sensei Biotherapeutics, Inc. - Common Stock

Sensei Biotherapeutics

Synlogic

Tharimmune

XOMA Royalty Corporation - 8.625% Series A Cumulative Perpetual Preferred Stock

XOMA Royalty

Roth MKM

Comments

Aptevo Therapeutics

Aptevo Therapeutics (APVO) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL